Powerchain network is a new DAG based platform allows blockless security and high speed transactions without mining. Powerchain is preparing 4 products for users.Powerstack wallet,Powerpay and its payment tool Powercard and Powerexchange. Powerstack, the highly anticipated mobile wallet for Powerchain and its digital asset $PCX. Powerstack is launched on Beta on Android. Powerstack V1.0 release for Android and IOS will be rolled out with additional features added in the near future. PowerPay, the first fast and convenient, ready to use crypto debit card, which can be used for everyday purchases anytime, anywhere. Powerchain will come with its very own physical card that can be used at ATMs. Transactions will only work with your own pincode, so even if you lose your card, no worries, no one else wil be able to use your Powerpay card. Powerchain Network is studying on integrating Powerstack wallet to Powerpay that allows owner to send PCX coins from wallet to Powerpay credit card. Powerchain announces the plans to develop our own Asset Exchange as mentioned on roadmap, POWEREXCHANGE. This strategic decision will further grow Powerchain coin position in the cryptocurrency market with larger scale and volume; allowing sustainability by continues funding and organic growth; while rewarding the community with profit sharing also promotes giving back to the community members by ensuring that 70% of the exchange’s revenue goes back to holders of PCX tokens.

All Public Art (APA) provides a unique platform that contributes to the growth and sustainability of the global art community by supporting the art market, igniting artist-to-collector trading, and storing the provenance of art on the blockchain. With the AllPublicArt token and the creation of our API, we are deploying a new, convenient and effective way to trade art and track the history of artworks. All Public Art's implementation of blockchain technology will minimize counterfeit art, build trust within the art market, improve art trade services and increase economic and social benefits in the global art community. Thanks to blockchain technology, transparency is increased ensuring a more convenient and legitimate marketplace for trading art.

Aimedis is an AI backed, blockchain and smart contract supported medical ecosystem, that changes the way patients, doctors, and hospitals communicate, connect and handle information. Using the Aimedis platform, users can store, secure and share their medical information only with the people they want to share it with by using the Aimedis right management system. Beside the records, AImedis offers videochat and communication with other patients and doctors, online prescriptions, online appointments, learning content, the inclusion of fitness trackers and devices like ECG or bloodpressure monitors into the system, while all transactions inside the system are backed by our porprietary private AIMChain blockchain, while the token is bound to a public blockchain (Aimedis dual-blockchain model). AIMSocial will be the new incentivised and decentralized medical social network where patients can help other patients and get rewarded for it, while the system is supported by AI.

The first sports community for fans, that covers the complete fan experience. Follow your favourite sports star, club or brand and get rewarded for engaging.

Pharmeum is the world's first blockchain-based prescription platform with AI health analytics, which is currently working alongside the National Health Service (NHS) in England. The Pharmeum platform is an inter-operable, decentralised, digital prescription platform running over an intelligent neural network. Empowering patients’ ownership of their medication history, and enabling affordable access to healthcare globally. Medical errors and late diagnoses are minimised by using a permissioned blockchain integrated with artificial intelligence. Pharmeum is an advanced, digitised, health eco-system.The Pharmeum blockchain will improve medicine affordability, minimise errors, and create frictionless, quality care for patients.